Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) - Global Forecast to 2028

Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) - Global Forecast to 2028

The global epigenetics market size is projected to reach USD 4.3 billion by 2028 from USD 1.8 billion in 2023, at a CAGR of 18.3% during the forecast period. Factors such as increased investments in research and development, coupled with a reduction in sequencing costs and time, support from government initiatives and funding for epigenetics research, advancements in technology for epigenetic research, and a growing interest in epigenetic-based therapeutics.

“The kits & reagents segment segment held the dominant share in the epigenetics market”

Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The kits & reagents segmentis anticipated to grow at significant CAGR. The rapid expansion of epigenetics studies, combined with the introduction of cost-effective and user-friendly kits by market participants are likely to have positive impact on the growth of the market.

“DNA methylation segment accounted for the largest share of the method segment in 2022.”

Based on method, the epigenetics market is segmented into, DNA methylation, histone modifications, and other methods. In 2022, the DNA methylation segment accounted for the largest share of the epigenetics market. The segment held the dominant share in the market owing to the effectiveness of employing DNA methylation techniques for cancer research.

“Asia Pacific region is likely to grow at a faster pace in the epigenetics market.”

The epigenetics market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by enhancements in healthcare infrastructure within developing APAC economies, coupled with strategic partnerships, collaborations, agreements, and expansions pursued by local industry players.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 60%, and Demand Side - 40%

By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%

By Region: North America: 40%, Europe: 27%, Asia Pacific: 20%, Latin America: 10%, and the Middle East & Africa: 3%

List of Companies Profiled in the Report:

Thermo Fisher Scientific Inc. (US)

Merck KGaA (Germany)

Illumina, Inc. (US)

PacBio (US)

Abcam plc (UK)

Active Motif, Inc. (US)

Bio-Rad Laboratories Inc. (US)

Promega Corporation (US)

Revvity (US)

Qiagen (Germany)

New England Biolabs (US)

Zymo Research Corporation (US)

Diagenode SA(US)

F. Hoffmann-La Roche Ltd (Switzerland)

EpiGentek Group Inc. (US)

EpiCypher (US)

Fios Genomics (UK)

GenomeScan (Netherlands)

Creative Biogene (US)

BPS Bioscienc Inc (US)

Abnova Corporation (Taiwan)

Creative Diagnostics (US)

Biomodal (UK)

Integrated DNA Technologies Inc. (US)

Novogene Co Ltd (China)

Research Coverage:

This report provides a detailed picture of the epigenetics market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall epigenetics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (growing investment in research & development, declining sequencing cost & time, favorable government initiatives and funding for epigenetics research, technological advancements in epigenetic research and rising demand for epigenetic-based therapeutics), restraints (Limited application of epigenomic data in toxicology, data privacy concern and security issues associated with management of large scale- epigenetic data ), opportunities (Expanding application of epigenetics and integration of artificial intelligence and machine learning algorithm) and challenges (Concerns Regarding the Quality of Antibodies, Challenges associated epigenetics editing, off target effect) are influencing the growth of epigenetics market.

Product Development/Innovation: Detailed insights on newly launched products of the epigenetics market.

Market Development: Comprehensive information about lucrative markets – the report analyses the epigenetics market across varied regions.

Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the epigenetics market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US) and Qiagen (Germany).